Glecaprevir-Pibrentasvir (Mavyret)

Table of Contents

- Glecaprevir-Pibrentasvir Mavyret Summary
- Drug Summary
- Adverse Effects
- Class and Mechanism
- Indications
- Dosing
- Cost and Medication Access
- Key Drug Interactions
- Figures

Drug Summary

Glecaprevir-pibrentasvir (Figure 1) and (Figure 2) is the first pangenotypic NS3/4A protease inhibitor-NS5A inhibitor combination to be approved that offers a potent treatment option for the vast majority of persons with chronic hepatitis C, including an 8-week option for treatment-naïve individuals. This drug is not an option for persons with decompensated cirrhosis (Child B/C) given the presence of the protease inhibitor. In the main registration trials, sustained virologic response rates for 8 or 12 weeks of glecaprevir-pibrentasvir for genotypes 1, 2, 5 or 6 were in the range of 98-100% with very few if any on-treatment virologic breakthroughs or post-treatment relapses.

Adverse Effects

The most common adverse effects, observed in at least 10% of phase 3 trial participants, were headache and fatigue.

Class and Mechanism

Glecaprevir (GLE, formerly ABT-493) is an NS3/4A protease inhibitor that prevents the cleavage of the HCV polyprotein. It has potent in vitro activity (on the order of less than or equal to 5 nanomolar), across the HCV genotypes including common HCV genotype 1 variants that have substitutions (at Q80, R155 and D168) conferring resistance to older-generation HCV protease inhibitors. Pibrentasvir (PIB, formerly ABT-530) is a next-generation NS5A inhibitor with pangenotypic activity in vitro; it maintains potent antiviral activity against common HCV NS5A single-position variants that confer resistance to first-generation NS5A inhibitors,
indicating daclatasvir, ledipasvir, and ombitasvir.

**Indications**

The 8-week course of glecaprevir-pibrentasvir is indicated for treatment-naïve persons with genotypes 1-6 HCV, including individuals without cirrhosis and those with compensated cirrhosis (Child-Pugh A). For treatment-experienced persons, the treatment course varies from 8 to 16 weeks, based on HCV genotype, the prior treatment regimen, and cirrhosis status. For complete information on glecaprevir-pibrentasvir-related indications, see the [Indications and Usage](#) section in the Glecaprevir-Pibrentasvir ([Mavyret](#)) Prescribing Information.

**Dosing**

Each fixed-dose tablet contains 100 mg of glecaprevir and 40 mg of pibrentasvir. The recommended oral dosage of glecaprevir-pibrentasvir in adults is 3 tablets taken at the same time once daily with food (total daily dose: glecaprevir 300 mg and pibrentasvir 120 mg).

**Cost and Medication Access**

AbbVie has an active glecaprevir-pibrentasvir patient assistance program for eligible persons with hepatitis C who do not have insurance or do not have coverage through Medicaid or Medicare. Information regarding the AbbVie glecaprevir-pibrentasvir patient assistance program can be obtained at the [myAbbVie Assist](#) website or by phone at 1-800-222-6885.

**Key Drug Interactions**

For complete information on glecaprevir-pibrentasvir-related drug interactions, see the [Drug Interactions section in the Glecaprevir-Pibrentasvir ([Mavyret](#)) Prescribing Information](#).

**Figures**

- **Figure 1. Fixed-Dose Tablet of Glecaprevir-Pibrentasvir ([Mavyret](#))**

Each fixed dose tablet contains 100 mg of glecaprevir and 40 mg of pibrentasvir. The recommended daily dose is 3 tablets once daily.
Figure 2. Glecaprevir-Pibrentasvir (Mavyret) Packaging

Note each daily packet contains 3 glecaprevir-pibrentasvir fixed-dose tablets and each tablet consists of 100 mg of glecaprevir and 40 mg of pibrentasvir.

This photograph is courtesy of AbbVie